0000000000543219

AUTHOR

Carlos Solano De La Asunción

showing 4 related works from this author

Caveats in interpreting SARS‐CoV‐2 IgM + /IgG − antibody profile in asymptomatic health care workers

2020

Serological testing is increasingly recognized as a useful tool for management of the COVID‐19 pandemic.1 Cross‐sectional serosurveys provide information on exposure levels in a target population, which is helpful for designing public health strategies to blunt community transmission.2 This article is protected by copyright. All rights reserved.

medicine.medical_specialty2019-20 coronavirus outbreakbusiness.industryPublic healthSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Target populationAsymptomaticVirology03 medical and health sciences0302 clinical medicineInfectious DiseasesAntibody ProfileVirologyHealth caremedicine030211 gastroenterology & hepatology030212 general & internal medicinemedicine.symptomSeroconversionbusinessIntensive care medicineJournal of Medical Virology
researchProduct

Cytomegalovirus‐specific T‐cell immunity and DNAemia in patients with chronic lymphocytic leukaemia undergoing treatment with ibrutinib

2021

CD4-Positive T-LymphocytesMaleCongenital cytomegalovirus infectionCytomegalovirusT-Cell Antigen Receptor SpecificityCD8-Positive T-LymphocytesViral Matrix Proteinschemistry.chemical_compoundPiperidinesT-Lymphocyte SubsetsT cell immunitymedicineHumansIn patientViremiaProtein Kinase InhibitorsAgedAged 80 and overLymphocytic leukaemiabusiness.industryAdenineHematologyCmv dnaemiaMiddle Agedmedicine.diseaseLeukemia Lymphocytic Chronic B-CellchemistryIbrutinibCytomegalovirus InfectionsDNA ViralImmunologyFemalebusinessInterferon-gamma Release TestsBritish Journal of Haematology
researchProduct

Field evaluation of a rapid antigen test (Panbio™ COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary healthcare centres.

2021

Abstract Objectives To our knowledge no previous study has assessed the performance of a rapid antigen diagnostic immunoassay (RAD) conducted at the point of care (POC). We evaluated the Panbio™ COVID-19 Ag Rapid Test Device for diagnosis of coronavirus 2019 disease (COVID-19) in symptomatic patients (n = 412) attending primary healthcare centres. Methods RAD was performed immediately after sampling following the manufacturer's instructions (reading at 15 min). RT-PCRs were carried out within 24 h of specimen collection. Samples displaying discordant results were processed for culture in Vero E6 cells. Presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in cell cultures…

0301 basic medicineMaleRapid antigen detection test (RAD)medicine.disease_causeAmbulatory Care Facilities0302 clinical medicineNasopharynx030212 general & internal medicineChildAntigens ViralCoronavirusAged 80 and overImmunoassaymedicine.diagnostic_testGeneral MedicineMiddle AgedEarly diagnosisResearch NoteInfectious DiseasesSpecimen collectionRapid antigen testPoint-of-Care TestingCOVID-19 Nucleic Acid TestingChild PreschoolFemaleMicrobiology (medical)Adultmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)AdolescentPoint-of-care testing030106 microbiologySensitivity and SpecificityCOVID-19 Serological Testing03 medical and health sciencesYoung AdultAntigenInternal medicinemedicineHumansPoint of careAgedbusiness.industrySARS-CoV-2COVID-19InfantImmunoassayReagent Kits DiagnosticbusinessPrimary healthcare centreClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
researchProduct

Suitability of two rapid lateral flow immunochromatographic assays for predicting SARS‐CoV‐2 neutralizing activity of sera

2020

Purpose: Assessment of commercial SARS-CoV-2 immunoassays for their capacity to provide reliable information on sera neutralizing activity is an emerging need. We evaluated the performance of two commercially-available lateral flow immunochromatographic assays (LFIC) (Wondfo SARS-CoV-2 Antibody test and the INNOVITA 2019-nCoV Ab test) in comparison with a SARS-CoV-2 neutralization pseudotyped assay for COVID-19 diagnosis in hospitalized patients, and investigate whether the intensity of the test band in LFIC associates with neutralizing antibody (NtAb) titers. Patients and Methods: Ninety sera were included from 51 patients with moderate to severe COVID-19. A green fluorescent protein (GFP)…

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Green Fluorescent ProteinsAntibodies ViralNeutralizing antibodiesNeutralizationSARS‐CoV‐2Green fluorescent protein03 medical and health sciencesCOVID-19 Testing0302 clinical medicineCOVID‐19VirologyLateral flow 16 immunochromatographic assaysHumansMedicineImmunochromatographic Assays030212 general & internal medicineNeutralizing antibodyResearch ArticlesImmunoassaybiologybusiness.industrySARS-CoV-2COVID-19biology.organism_classificationAntibodies NeutralizingVirologyTiterInfectious DiseasesImmunoglobulin MVesicular stomatitis virusImmunoglobulin GSpike Glycoprotein Coronavirusbiology.proteinlateral flow immunochromatographic assays030211 gastroenterology & hepatologyLteral flow immunochromatographic assaysAntibodybusinessResearch Article
researchProduct